Methods for using human monoclonal antibodies to interleukin-5
View Patent ↗The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IL-5 antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IL-5 antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IL-5 antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
1. A method for treating a condition or disorder in which IL-5 activity is detrimental, comprising the step of administering to a subject in need thereof an effective amount of an antibody or antigen-binding fragment thereof that specifically binds IL-5, wherein said antibody or antigen-binding fragment comprises:
(a) a heavy chain amino acid sequence comprising the CDR1, CDR2 and CDR3 amino acid sequences shown in SEQ ID NOS: 8, 10 and 12, respectively; and
(b) a light chain amino acid sequence comprising the CDR1, CDR2 and CDR3 amino acid sequences shown in SEQ ID NOS: 14, 16 and 18, respectively,
wherein the condition or disorder is asthma.
2. The method according to claim 1 , wherein the antibody or antigen-binding fragment decreases or inhibits the infiltration of eosinophils into affected tissue.
3. The method according to claim 2 , wherein the anti-IL-5 antibody is administered in conjunction with the administration of another therapeutic agent.
4. A method for treating an IL-5 mediated allergic response in a subject, comprising the step of administering to a subject in need thereof an effective amount of an antibody or antigen-binding fragment thereof that specifically binds IL-5, wherein said antibody or antigen-binding fragment comprises:
(a) a heavy chain amino acid sequence comprising the CDR1, CDR2 and CDR3 amino acid sequences shown in SEQ ID NOS: 8, 10 and 12, respectively; and
(b) a light chain amino acid sequence comprising the CDR1, CDR2 and CDR3 amino acid sequences shown in SEQ ID NOS: 14, 16 and 18, respectively.
5. The method of claim 4 , wherein the IL-5 mediated allergic response is asthma.
6. A method for treating an IL-5 mediated event selected from the group consisting of:
(a) eosinophil proliferation, maturation, survival, activation, migration into the bloodstream, adhesion to endothelium, infiltration into tissues;
(b) pulmonary edema;
(c) bronchoconstriction;
(d) airway hyperresponsiveness;
(e) pulmonary eosinophilia or neutrophilia;
(f) cutaneous eosinophilia; and
(g) airway epithelial damage, comprising the step of administering to a subject in need thereof an effective amount of an antibody or antigen-binding fragment thereof that specifically binds IL-5, wherein said antibody or fragment comprises:
(a) a heavy chain amino acid sequence comprising the CDR1, CDR2 and CDR3 amino acid sequences shown in SEQ ID NOS: 8, 10 and 12, respectively; and
(b) a light chain amino acid sequence comprising the CDR1, CDR2 and CDR3 amino acid sequences shown in SEQ ID NOS: 14, 16 and 18, respectively.